Contemporary use of bevacizumab in ovarian cancer.

Abstract

INTRODUCTION:

Ovarian cancer remains the most lethal gynecologic malignancy. Although standard platinum-based chemotherapy results in high response rates, more than 70% of patients with advanced disease will experience recurrence within 5 years. Therefore, novel treatment strategies to increase primary efficacy, decrease recurrence after primary treatment and improve the response rate for recurrent disease are needed.

AREAS COVERED:

This review covers antiangiogenesis therapy and the efficacy of bevacizumab as primary treatment and in platinum-sensitive and resistant recurrent disease.

EXPERT OPINION:

The evidence provided from Phase III trials has supported the efficacy of bevacizumab in primary and recurrent ovarian cancer management. Future investigation is needed to improve clinical performance (via biomarkers of efficacy, early discontinuation, additional agents, etc.), as well as, more sensitive tools to assess direct patient impact.

• Authors: Takahito M Miyake, Anil K Sood, Robert L Coleman
• Journal: Expert opinion on biological therapy (Expert Opin Biol Ther) Vol. 13 Issue 2 Pg. 283-94 (Feb 2013) ISSN: 1744-7682 [Electronic] England
• PMID: 23190436 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Review)

Chemical References

• Antibodies, Monoclonal, Humanized
• Vascular Endothelial Growth Factor A
• Bevacizumab

Topics

• Antibodies, Monoclonal, Humanized (therapeutic use)
• Bevacizumab
• Clinical Trials, Phase II as Topic
• Clinical Trials, Phase III as Topic
• Female
• Humans
• Neovascularization, Pathologic
• Ovarian Neoplasms (blood supply, drug therapy, metabolism)
• Vascular Endothelial Growth Factor A (metabolism)